Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
Journal
The Lancet. Oncology
ISSN: 1474-5488
Titre abrégé: Lancet Oncol
Pays: England
ID NLM: 100957246
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
06
11
2019
revised:
13
12
2019
accepted:
23
12
2019
pubmed:
28
2
2020
medline:
10
7
2020
entrez:
28
2
2020
Statut:
ppublish
Résumé
The selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and long-term safety of larotrectinib in a larger population of patients with TRK fusion-positive solid tumours. Patients were enrolled and treated in a phase 1 adult, a phase 1/2 paediatric, or a phase 2 adolescent and adult trial. Some eligibility criteria differed between these studies. For this pooled analysis, eligible patients were aged 1 month or older, with a locally advanced or metastatic non-CNS primary, TRK fusion-positive solid tumour, who had received standard therapy previously if available. This analysis set includes the 55 patients on which approval of larotrectinib was based. Larotrectinib was administered orally (capsule or liquid formulation), on a continuous 28-day schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patients mostly at a dose of 100 mg/m Between May 1, 2014, and Feb 19, 2019, 159 patients with TRK fusion-positive cancer were enrolled and treated with larotrectinib. Ages ranged from less than 1 month to 84 years. The proportion of patients with an objective response according to investigator assessment was 121 (79%, 95% CI 72-85) of 153 evaluable patients, with 24 (16%) having complete responses. In a safety population of 260 patients treated regardless of TRK fusion status, the most common grade 3 or 4 larotrectinib-related adverse events were increased alanine aminotransferase (eight [3%] of 260 patients), anaemia (six, 2%), and decreased neutrophil count (five [2%]). The most common larotrectinib-related serious adverse events were increased alanine aminotransferase (two [<1%] of 260 patients), increased aspartate aminotransferase (two [<1%]), and nausea (two [<1%]). No treatment-related deaths occurred. These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active. Safety data indicate that long-term administration of larotrectinib is feasible. Bayer and Loxo Oncology.
Sections du résumé
BACKGROUND
The selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and long-term safety of larotrectinib in a larger population of patients with TRK fusion-positive solid tumours.
METHODS
Patients were enrolled and treated in a phase 1 adult, a phase 1/2 paediatric, or a phase 2 adolescent and adult trial. Some eligibility criteria differed between these studies. For this pooled analysis, eligible patients were aged 1 month or older, with a locally advanced or metastatic non-CNS primary, TRK fusion-positive solid tumour, who had received standard therapy previously if available. This analysis set includes the 55 patients on which approval of larotrectinib was based. Larotrectinib was administered orally (capsule or liquid formulation), on a continuous 28-day schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patients mostly at a dose of 100 mg/m
FINDINGS
Between May 1, 2014, and Feb 19, 2019, 159 patients with TRK fusion-positive cancer were enrolled and treated with larotrectinib. Ages ranged from less than 1 month to 84 years. The proportion of patients with an objective response according to investigator assessment was 121 (79%, 95% CI 72-85) of 153 evaluable patients, with 24 (16%) having complete responses. In a safety population of 260 patients treated regardless of TRK fusion status, the most common grade 3 or 4 larotrectinib-related adverse events were increased alanine aminotransferase (eight [3%] of 260 patients), anaemia (six, 2%), and decreased neutrophil count (five [2%]). The most common larotrectinib-related serious adverse events were increased alanine aminotransferase (two [<1%] of 260 patients), increased aspartate aminotransferase (two [<1%]), and nausea (two [<1%]). No treatment-related deaths occurred.
INTERPRETATION
These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active. Safety data indicate that long-term administration of larotrectinib is feasible.
FUNDING
Bayer and Loxo Oncology.
Identifiants
pubmed: 32105622
pii: S1470-2045(19)30856-3
doi: 10.1016/S1470-2045(19)30856-3
pmc: PMC7497841
mid: NIHMS1620306
pii:
doi:
Substances chimiques
Proteins
0
Pyrazoles
0
Pyrimidines
0
TFG protein, human
0
larotrectinib
PF9462I9HX
Banques de données
ClinicalTrials.gov
['NCT02122913', 'NCT02637687', 'NCT02576431']
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
531-540Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA226864
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
Target Oncol. 2018 Oct;13(5):545-556
pubmed: 30276762
Cancer Discov. 2018 Oct;8(10):1227-1236
pubmed: 30093503
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Cancer Discov. 2015 Oct;5(10):1049-57
pubmed: 26216294
Cancer Cell. 2002 Nov;2(5):367-76
pubmed: 12450792
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
Am J Surg Pathol. 2010 May;34(5):599-608
pubmed: 20410810
Am J Surg Pathol. 2000 Jul;24(7):937-46
pubmed: 10895816
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747
pubmed: 30333516
N Engl J Med. 2002 Aug 15;347(7):472-80
pubmed: 12181401
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancer Discov. 2017 Apr;7(4):400-409
pubmed: 28183697
Lancet Oncol. 2018 May;19(5):705-714
pubmed: 29606586
Nat Med. 2019 Sep;25(9):1422-1427
pubmed: 31406350
J Clin Pathol. 2019 Jul;72(7):460-467
pubmed: 31072837
N Engl J Med. 2014 Nov 20;371(21):1963-71
pubmed: 25264305
Cell Rep. 2018 Jul 10;24(2):515-527
pubmed: 29996110
JCO Precis Oncol. 2019 May 16;3:
pubmed: 32914009
Pathology. 2016 Jan;48(1):47-50
pubmed: 27020209
Ann Oncol. 2019 Sep 1;30(9):1417-1427
pubmed: 31268127
Cancer Res. 2019 Mar 15;79(6):1047-1053
pubmed: 30643016
Cancer Discov. 2017 Sep;7(9):963-972
pubmed: 28578312